Bristol Myers Squibb Co. (BMY)

59.87
0.42 0.70
NYSE : Health Technology
Prev Close 60.29
Open 60.32
Day Low/High 59.28 / 60.68
52 Wk Low/High 42.48 / 68.34
Volume 10.51M
Avg Volume 15.45M
Exchange NYSE
Shares Outstanding 2.26B
Market Cap 136.42B
EPS 2.00
P/E Ratio 95.54
Div & Yield 1.80 (2.86%)

Latest News

SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities

SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities

I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.

This Chart Pattern Hints at a Bullish Future

This Chart Pattern Hints at a Bullish Future

The bullish reversal pattern is appearing not just in single names, but also in whole sectors.

Trading Volume, Late Selloffs, Peloton's Run Higher

Trading Volume, Late Selloffs, Peloton's Run Higher

As Treasury heads for longer-dated issuance and names like PTON run higher on earnings, selloffs late in the trading day continue.

Genprex Is Soaring - And There's a One Word Reason Why

Genprex Is Soaring - And There's a One Word Reason Why

The small biotech's market cap sits at $125 million, the low end of what I believe is fair.

Jim Cramer: Here Are the Stocks That 'Transom' Money Is Buying

Jim Cramer: Here Are the Stocks That 'Transom' Money Is Buying

They buy and buy and buy. The same stocks. Over and over. No end to it.

Jim Cramer: Goodbye to a Horrid Quarter

Jim Cramer: Goodbye to a Horrid Quarter

Now that the service economy is pretty much stopped in its tracks, here are promising areas, including technology as manufacturing, to consider.

Bear Markets Do End, But What Should Investors Be Doing Now?

Bear Markets Do End, But What Should Investors Be Doing Now?

At the end of the day, investors really have only three choices to make when managing an investment portfolio -- buy, hold, or sell.

Three Strategies for Income Investors

Three Strategies for Income Investors

For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.

Watch These Biotech Names on Strong Earnings

Watch These Biotech Names on Strong Earnings

Merger activity is the number 1 driver I am watching for biotech growth.

China Reduces Tariffs, 20 Year Treasury Bonds, Pricey Peloton: Market Recon

China Reduces Tariffs, 20 Year Treasury Bonds, Pricey Peloton: Market Recon

This move by Beijing comes on top of massive injections of liquidity into that nation's financial system earlier this week.

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

These companies all could be strong -- even if the 2019 nCoV fear spreads.

Jim Cramer: Larry Fink Is Showing What True Leadership Looks Like

Jim Cramer: Larry Fink Is Showing What True Leadership Looks Like

BlackRock's CEO will now make investment decisions based on a company's commitment to environmental sustainability. You can bet the financial world will never be the same again.

Jim Cramer: The HQ for Innovation Is Right Here in San Francisco

Jim Cramer: The HQ for Innovation Is Right Here in San Francisco

The NYSE used to be the center of capitalism, but now it's where actual engineering, not financial engineering, is taking place.

Bristol-Myers Squibb's Stock Could Soar to New All-Time Highs This Quarter

Bristol-Myers Squibb's Stock Could Soar to New All-Time Highs This Quarter

Let's review the charts.

4 Favorite Biotech Stock Picks for 2020

4 Favorite Biotech Stock Picks for 2020

The Medical Technology Stock Letter's top pick rose 357% in 2019.

Jim Cramer: Don't Get Sacked in This Political Football Match

Jim Cramer: Don't Get Sacked in This Political Football Match

How to prepare your portfolio and be opportunistic in the face of this geopolitical instability.

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.

Bristol-Myers Squibb May Trade Sideways for a Bit but Expect New Highs Later

Bristol-Myers Squibb May Trade Sideways for a Bit but Expect New Highs Later

The drugmaker's shares are up about 50% since last July and could use a rest, but are likely to move higher longer term.

3 Boomer-Inspired Drug Plays With Dividend Appeal

3 Boomer-Inspired Drug Plays With Dividend Appeal

Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.

Jim Cramer: Why Doesn't Impeachment Matter More to the Market?

Jim Cramer: Why Doesn't Impeachment Matter More to the Market?

The impeachment and trial of President Trump has nothing to do with the price to earnings ratio of Bristol-Myers or any other stock for that matter.

3 Biotech Stocks With the Best-Looking Charts

3 Biotech Stocks With the Best-Looking Charts

Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.

Jim Cramer: Be Cautious Today, the Tape Feels Bad

Jim Cramer: Be Cautious Today, the Tape Feels Bad

We are playing defense as we see some downward pressure on oil and healthcare weakness.

Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead

Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead

There may be sideways action in the drugmaker's shares in the near term, but a strong move higher is possible down the road.

Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not

Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not

We're seeing lots of companies snapping up their peers, and the market is applauding.

News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon

News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon

Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.

Jim Cramer: Nothing's Changed, Except the Prices

Jim Cramer: Nothing's Changed, Except the Prices

The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.

Bristol-Myers Stock Has the Right Prescription

Bristol-Myers Stock Has the Right Prescription

BMY can soar still higher in the months ahead.